NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/16/2024
Back to search
Official data from USPTO
TRANSFORMATIVE PHARMACEUTICAL SOLUTIONS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TRANSFORMATIVE PHARMACEUTICAL SOLUTIONS
ST13
US500000086794366Class
35
Filing
86794366
Registration
5617769
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
49
Latest update
10/16/2024
Trademark type
Word
Nice classes
35
Filing date
10/21/2015
Registration date
11/27/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/16/2024
Last transaction
10/16/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2016-09-00
First use in commerce
2016-09-00
Drawing code
4
Owner type
16
Owner location
Blue Bell, PA, US
Examiner
MURRAY, GEORGE WILLIAM
Current location
Historical data usage
Holders and representatives
Holders
Transformative Pharmaceutical Solutions, LLC
Representatives
Susan A. Smith Ballard Spahr LLP
Technical classification
Nice Classes
Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
clinical research site management and monitoringidentifyingqualifyingselecting sites for clinical trialsnegotiating clinical trial site contracts and budgetsorganizing and conducting business meetings of clinical trial investigatorsassisting investigators with developing business strategies for recruiting clinical trial participantssubmitting clinical trial protocols to institutional review boards and independent ethics committeesmonitoring clinical trial investigators' activities for compliance with clinical protocols and regulations and for patient safety; employment staffing in the field of clinical trials; business information management; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalpharmaceuticalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for drug approval; business project management in the field of clinical trials; providing the services of vendor management to medicalpharmaceuticalbiopharmaceutical and biotechnology companiesselecting and managing third-party providers of services that support clinical trials
Publications
History of USPTO decisions and trademark events.
49 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/16/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/16/2024
E815
TEAS SECTION 8 & 15 RECEIVED
04/17/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/27/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/27/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/27/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/27/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/27/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/27/2018
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/26/2018
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/25/2018
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/25/2018
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/25/2018
IUAF
USE AMENDMENT FILED
10/01/2018
EISU
TEAS STATEMENT OF USE RECEIVED
10/01/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/15/2018
EX1G
SOU EXTENSION 1 GRANTED
03/13/2018
EXT1
SOU EXTENSION 1 FILED
03/13/2018
EEXT
SOU TEAS EXTENSION RECEIVED
03/13/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/28/2017
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/18/2017
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/18/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2017
PUBO
PUBLISHED FOR OPPOSITION
10/03/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/13/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/28/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/22/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/16/2017
GNSL
LETTER OF SUSPENSION E-MAILED
02/16/2017
CNSL
SUSPENSION LETTER WRITTEN
02/16/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/08/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/08/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/08/2017
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/16/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/16/2016
GNSL
LETTER OF SUSPENSION E-MAILED
06/16/2016
CNSL
SUSPENSION LETTER WRITTEN
06/16/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/09/2016
ALIE
ASSIGNED TO LIE
06/02/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/20/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/19/2016
GNRT
NON-FINAL ACTION E-MAILED
02/19/2016
CNRT
NON-FINAL ACTION WRITTEN
02/19/2016
DOCK
ASSIGNED TO EXAMINER
02/11/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/26/2015
NWAP
NEW APPLICATION ENTERED
10/24/2015
Continuous trademark protection
Get notified about every new filing that threatens TRANSFORMATIVE PHARMACEUTICAL SOLUTIONS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.